TransMedics Group, Inc. $TMDX Shares Acquired by Valmark Advisers Inc.

Key Points

• Valmark Advisers Inc. has increased its stake in TransMedics Group by 34.6%, holding 9,709 shares valued at approximately $1.3 million.
• Analysts have provided mixed ratings for TransMedics Group, with a current average target price of $125.40, indicating a "Moderate Buy" rating.
• TransMedics Group reported a quarterly earnings per share of $0.92, surpassing estimates, with a revenue increase of 37.7% compared to the same period last year.

Valmark Advisers Inc. increased its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 34.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,709 shares of the company's stock after acquiring an additional 2,496 shares during the period. Valmark Advisers Inc.'s holdings in TransMedics Group were worth $1,301,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. NBC Securities Inc. acquired a new stake in TransMedics Group during the first quarter worth about $25,000. Opal Wealth Advisors LLC acquired a new stake in TransMedics Group during the second quarter worth about $26,000. Smartleaf Asset Management LLC grew its holdings in TransMedics Group by 44.3% during the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock worth $30,000 after acquiring an additional 135 shares during the period. Quarry LP grew its holdings in TransMedics Group by 88.5% during the first quarter. Quarry LP now owns 592 shares of the company's stock worth $40,000 after acquiring an additional 278 shares during the period. Finally, Sound Income Strategies LLC acquired a new stake in TransMedics Group during the second quarter worth about $48,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TMDX has been the topic of several analyst reports. Stifel Nicolaus initiated coverage on TransMedics Group in a report on Thursday, September 4th. They set a "hold" rating and a $115.00 target price on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a report on Monday, August 25th. Morgan Stanley increased their price target on TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a research report on Friday, August 1st. Canaccord Genuity Group increased their price target on TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a research report on Tuesday, July 15th. Finally, Oppenheimer increased their price target on TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 17th. Six equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, TransMedics Group presently has an average rating of "Moderate Buy" and an average target price of $125.40.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $112.98 on Friday. The company has a market capitalization of $3.85 billion, a P/E ratio of 58.54 and a beta of 2.08. The business's 50 day moving average is $117.48 and its two-hundred day moving average is $111.57. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $145.50. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.44. The business had revenue of $157.37 million for the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The business's quarterly revenue was up 37.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. Analysts expect that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.